The lawsuits Novo Nordisk has brought against compounding pharmacies for a variety of things such as the pharmacies claiming they were selling "Ozempic" rather than semiglutide and/or that their compounded product was FDA-approved.
In certain circumstances such as inability to meet demand, compounding pharmacies are legally allowed to infringe on those companies' patents and sell products which are substantially similar to their own patented products. The Drug Quality and Security Act of 2018 does not allow those compounding pharmacies to sell such products using trademarks or branding, nor to claim FDA approval for their compounded products.
Considering how the voting public is embracing these GLP-1 products and demanding access, I suspect Novo Nordisk, Eli Lilly, et al. can lobby all they want to repeal the DQ&S Act, but I don't see them being successful. The best moves such companies have been to increase their production thus removing that essential qualification of DQ&S protections for compounding pharmacies.